Category: Press Release - Page 144 - Psychedelic Alpha

Explore our new Pα+ Psychedelic Bill Tracker.

Numinus Wellness Inc. Announces $30 Million Bought Deal Public Offering

Post published:March 15, 2021
Post category:Press Release

Read more about the article Aion Therapeutic Files 4 New Patent Applications (Including for the Treatment of Human Cancers)

Aion Therapeutic Files 4 New Patent Applications (Including for the Treatment of Human Cancers)

Post published:March 11, 2021
Post category:Press Release

Read more about the article Octarine Bio announces closing of extended seed round financing of $1.2 million USD with an uptick in valuation due to significant investor demand.

Octarine Bio announces closing of extended seed round financing of $1.2 million USD with an uptick in valuation due to significant investor demand.

Post published:March 11, 2021
Post category:Press Release

Read more about the article BetterLife Subsidiary, Altum Pharmaceuticals, to Conduct Randomized Placebo-controlled COVID-19 Trial Using AP-003

BetterLife Subsidiary, Altum Pharmaceuticals, to Conduct Randomized Placebo-controlled COVID-19 Trial Using AP-003

Post published:March 11, 2021
Post category:Press Release

Read more about the article NeonMind Engages Certara to Advance its Synthetic Psilocybin Drug Candidates for Obesity

NeonMind Engages Certara to Advance its Synthetic Psilocybin Drug Candidates for Obesity

Post published:March 11, 2021
Post category:Press Release

Read more about the article Nova Mentis Upgrades U.S. Listing to the OTCQB Venture Market

Nova Mentis Upgrades U.S. Listing to the OTCQB Venture Market

Post published:March 10, 2021
Post category:Press Release

Read more about the article DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a Study as First Clinical Trial in Opioid Use Disorder in the UK

DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a Study as First Clinical Trial in Opioid Use Disorder in the UK

Post published:March 10, 2021
Post category:Press Release

Read more about the article Mydecine Innovations Group Announces Plans to Spin Out of its [U.S.] Cannabis Assets

Mydecine Innovations Group Announces Plans to Spin Out of its [U.S.] Cannabis Assets

Post published:March 10, 2021
Post category:Press Release

Read more about the article MindMed Increases Cash on Hand to CAD $205.2m (USD $162m), Closes Financing of CAD $19.5m (USD $15.4m)

MindMed Increases Cash on Hand to CAD $205.2m (USD $162m), Closes Financing of CAD $19.5m (USD $15.4m)

Post published:March 9, 2021
Post category:Press Release

Read more about the article Cybin Announces API Synthesis and Optimization of Multiple Tryptamine Derivatives and Nomination of Two Deuterated Candidates for Full IND Enabling Studies Based on Second Milestone Achievement Pursuant to the Adelia Acquisition

Cybin Announces API Synthesis and Optimization of Multiple Tryptamine Derivatives and Nomination of Two Deuterated Candidates for Full IND Enabling Studies Based on Second Milestone Achievement Pursuant to the Adelia Acquisition

Post published:March 9, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.